TrialPharmacology research & perspectives2021

A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.

Chay Ngee Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.